---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-344645"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2026-08-11T20:11:16+00:00"
generated_at: "2026-08-11T20:12:10.774222+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology Q2 2026: positive Phase 2 mCRC data, FDA aligned on Phase 3, licensing dispute

## Summary
- Q2 2026 cash ~$34.5M; six-month net cash burn $24.1M vs $21.1M in 2025; runway into Q3 2027
- Phase 2 CRDF-004: 30mg onvansertib+FOLFIRI/bev confirmed ORR 72.2% vs 42.1% for SoC; PFS HR 0.55 (BICR)
- Completed FDA End-of-Phase 2 meeting; aligned on Phase 3 design; initiation planned Q1 2027 subject to financing
- Completed $10M registered direct offering in July 2026 to extend cash runway
- Licensor NMS alleged material breach and terminated license; Cardiff filed lawsuit in May 2026 seeking declaratory relief

## SEC filing metadata
- accession: 0001193125-26-344645
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2026-08-11T20:11:16+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000119312526344645/0001193125-26-344645-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000119312526344645/crdf-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-344645
- JSON: https://secwatch.observer/filing/0001193125-26-344645.json
- Plain text: https://secwatch.observer/filing/0001193125-26-344645.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.